Oncocyte Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| ONCOCYTE CORPORATION | |
| By: | /s/ Josh Riggs |
| Josh Riggs | |
| President and Chief Executive Officer (Principal Executive Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Josh Riggs | President and Chief Executive Officer and Director | April 15, 2024 |
| JOSH RIGGS | (Principal Executive Officer) | |
| /s/ James Liu | Controller, Principal Accounting Officer and interim | April 15, 2024 |
| JAMES LIU | Principal Financial Officer (Principal Financial Officer) | |
| /s/ Andrew Arno | Director | April 15, 2024 |
| ANDREW ARNO | ||
| /s/ Alfred D. Kingsley | Director | April 15, 2024 |
| ALFRED D. KINGSLEY | ||
| /s/ Andrew J. Last | Director | April 15, 2024 |
| ANDREW J. LAST | ||
| /s/ Louis E. Silverman | Director | April 15, 2024 |
| LOUIS E. SILVERMAN | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.